カテゴリー： 世界, 医療/バイオ, LP Information

世界のT細胞・NK細胞結合型二重特異性抗体市場予測 2023年-2029年

【英語タイトル】Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Growth 2023-2029

LP Informationが出版した調査資料（LP23MY3711）・商品コード：LP23MY3711
・発行会社（調査会社）：LP Information
・発行日：2023年5月（※2025年版があります。お問い合わせください。）
・ページ数：123
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医療機器＆消耗品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥527,040見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥790,560見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,054,080見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界のT細胞・NK細胞結合型二重特異性抗体市場」は、過去の販売実績から2022年の世界のT細胞・NK細胞結合型二重特異性抗体の総販売量を検討し、2023年から2029年の予測されるT細胞・NK細胞結合型二重特異性抗体の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別のT細胞・NK細胞結合型二重特異性抗体の市場規模を掲載し、XXX百万米ドル規模の世界のT細胞・NK細胞結合型二重特異性抗体市場の詳細な分析を提供します。本インサイトレポートは、世界のT細胞・NK細胞結合型二重特異性抗体業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界のT細胞・NK細胞結合型二重特異性抗体市場における各社の独自のポジションをより深く理解するために、T細胞・NK細胞結合型二重特異性抗体製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界のT細胞・NK細胞結合型二重特異性抗体市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。T細胞・NK細胞結合型二重特異性抗体の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。T細胞・NK細胞結合型二重特異性抗体の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。T細胞・NK細胞結合型二重特異性抗体のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

T細胞・NK細胞結合型二重特異性抗体の世界主要メーカーとしては、AbbVie、 Astellas Pharma、 GEMoaB Monoclonals、 Immunocore、 Molecular Partners、 Roche、 AstraZeneca、 Merck & Co.、 Pfizer、 Eli Lilly、 IGM Biosciences、 Novartis、 BenHealth Biopharmaceuticals、 CytomX Therapeutics、 Janssen、 Lava Therapeutics、 MacroGenics、 Maverick Therapeutics、 VBL Therapeutics、 Amgenなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別のT細胞・NK細胞結合型二重特異性抗体市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査ではT細胞・NK細胞結合型二重特異性抗体市場をセグメンテーションし、種類別 (組換えモノクローナル抗体、自社製二重特異性抗体)、用途別 (がん免疫療法、臨床実験)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：組換えモノクローナル抗体、自社製二重特異性抗体

・用途別区分：がん免疫療法、臨床実験

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界のT細胞・NK細胞結合型二重特異性抗体市場の10年間の市場状況・展望は？
・世界および地域別に見たT細胞・NK細胞結合型二重特異性抗体市場成長の要因は何か？
・T細胞・NK細胞結合型二重特異性抗体の市場機会はエンドマーケットの規模によってどのように変化するのか？
・T細胞・NK細胞結合型二重特異性抗体のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：T細胞・NK細胞結合型二重特異性抗体の年間販売量2018-2029、地域別現状・将来分析
・T細胞・NK細胞結合型二重特異性抗体の種類別セグメント：組換えモノクローナル抗体、自社製二重特異性抗体
・T細胞・NK細胞結合型二重特異性抗体の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・T細胞・NK細胞結合型二重特異性抗体の用途別セグメント：がん免疫療法、臨床実験
・T細胞・NK細胞結合型二重特異性抗体の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界のT細胞・NK細胞結合型二重特異性抗体市場
・企業別のグローバルT細胞・NK細胞結合型二重特異性抗体市場データ：2018-2023年の年間販売量、市場シェア
・企業別のT細胞・NK細胞結合型二重特異性抗体の年間売上：2018-2023年の売上、市場シェア
・企業別のT細胞・NK細胞結合型二重特異性抗体販売価格
・主要企業のT細胞・NK細胞結合型二重特異性抗体生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

T細胞・NK細胞結合型二重特異性抗体の地域別レビュー
・地域別のT細胞・NK細胞結合型二重特異性抗体市場規模2018-2023：年間販売量、売上
・主要国別のT細胞・NK細胞結合型二重特異性抗体市場規模2018-2023：年間販売量、売上
・南北アメリカのT細胞・NK細胞結合型二重特異性抗体販売の成長
・アジア太平洋のT細胞・NK細胞結合型二重特異性抗体販売の成長
・ヨーロッパのT細胞・NK細胞結合型二重特異性抗体販売の成長
・中東・アフリカのT細胞・NK細胞結合型二重特異性抗体販売の成長

南北アメリカ市場
・南北アメリカの国別のT細胞・NK細胞結合型二重特異性抗体販売量、売上（2018-2023）
・南北アメリカのT細胞・NK細胞結合型二重特異性抗体の種類別販売量
・南北アメリカのT細胞・NK細胞結合型二重特異性抗体の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別のT細胞・NK細胞結合型二重特異性抗体販売量、売上（2018-2023）
・アジア太平洋のT細胞・NK細胞結合型二重特異性抗体の種類別販売量
・アジア太平洋のT細胞・NK細胞結合型二重特異性抗体の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別のT細胞・NK細胞結合型二重特異性抗体販売量、売上（2018-2023）
・ヨーロッパのT細胞・NK細胞結合型二重特異性抗体の種類別販売量
・ヨーロッパのT細胞・NK細胞結合型二重特異性抗体の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別のT細胞・NK細胞結合型二重特異性抗体販売量、売上（2018-2023）
・中東・アフリカのT細胞・NK細胞結合型二重特異性抗体の種類別販売量
・中東・アフリカのT細胞・NK細胞結合型二重特異性抗体の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・T細胞・NK細胞結合型二重特異性抗体の製造コスト構造分析
・T細胞・NK細胞結合型二重特異性抗体の製造プロセス分析
・T細胞・NK細胞結合型二重特異性抗体の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・T細胞・NK細胞結合型二重特異性抗体の主要なグローバル販売業者
・T細胞・NK細胞結合型二重特異性抗体の主要なグローバル顧客

地域別のT細胞・NK細胞結合型二重特異性抗体市場予測レビュー
・地域別のT細胞・NK細胞結合型二重特異性抗体市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・T細胞・NK細胞結合型二重特異性抗体の種類別市場規模予測
・T細胞・NK細胞結合型二重特異性抗体の用途別市場規模予測

主要企業分析
AbbVie、 Astellas Pharma、 GEMoaB Monoclonals、 Immunocore、 Molecular Partners、 Roche、 AstraZeneca、 Merck & Co.、 Pfizer、 Eli Lilly、 IGM Biosciences、 Novartis、 BenHealth Biopharmaceuticals、 CytomX Therapeutics、 Janssen、 Lava Therapeutics、 MacroGenics、 Maverick Therapeutics、 VBL Therapeutics、 Amgen
・企業情報
・T細胞・NK細胞結合型二重特異性抗体製品
・T細胞・NK細胞結合型二重特異性抗体販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

A Bispecific Antibodies is designed to bind two different targets or epitopes and can thereby exert two different functions. They are currently used to treat infectious, inflammatory, and malignant diseases.
LPI (LP Information)’ newest research report, the “T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Forecast” looks at past sales and reviews total world T-Cell & NK-Cell Engaging Bispecific Antibodies sales in 2022, providing a comprehensive analysis by region and market sector of projected T-Cell & NK-Cell Engaging Bispecific Antibodies sales for 2023 through 2029. With T-Cell & NK-Cell Engaging Bispecific Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world T-Cell & NK-Cell Engaging Bispecific Antibodies industry.
This Insight Report provides a comprehensive analysis of the global T-Cell & NK-Cell Engaging Bispecific Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on T-Cell & NK-Cell Engaging Bispecific Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global T-Cell & NK-Cell Engaging Bispecific Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for T-Cell & NK-Cell Engaging Bispecific Antibodies and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global T-Cell & NK-Cell Engaging Bispecific Antibodies.
The global T-Cell & NK-Cell Engaging Bispecific Antibodies market size is projected to grow from US$ 461.7 million in 2022 to US$ 588.9 million in 2029; it is expected to grow at a CAGR of 588.9 from 2023 to 2029.
Global key players of T-Cell & NK-Cell engaging bispecific antibodies include Amgen and Immunocore. These two manufactures hold the total market share in the world. The key players are mainly located in Europe and North America. In terms of product, T-Cell engagers is the largest segment, with a share over 93%. And in terms of application, the largest application is solid tumors, with a share over 71%.
This report presents a comprehensive overview, market shares, and growth opportunities of T-Cell & NK-Cell Engaging Bispecific Antibodies market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Recombinant Monoclonal Antibodies
In-House Bispecific Antibodies
Segmentation by application
Immunotherapy of Cancer
Clinical Experiment
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
AbbVie
Astellas Pharma
GEMoaB Monoclonals
Immunocore
Molecular Partners
Roche
AstraZeneca
Merck & Co.
Pfizer
Eli Lilly
IGM Biosciences
Novartis
BenHealth Biopharmaceuticals
CytomX Therapeutics
Janssen
Lava Therapeutics
MacroGenics
Maverick Therapeutics
VBL Therapeutics
Amgen
Key Questions Addressed in this Report
What is the 10-year outlook for the global T-Cell & NK-Cell Engaging Bispecific Antibodies market?
What factors are driving T-Cell & NK-Cell Engaging Bispecific Antibodies market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do T-Cell & NK-Cell Engaging Bispecific Antibodies market opportunities vary by end market size?
How does T-Cell & NK-Cell Engaging Bispecific Antibodies break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for T-Cell & NK-Cell Engaging Bispecific Antibodies by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for T-Cell & NK-Cell Engaging Bispecific Antibodies by Country/Region, 2018, 2022 & 2029
2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Type
2.2.1 Recombinant Monoclonal Antibodies
2.2.2 In-House Bispecific Antibodies
2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type
2.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2018-2023)
2.3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue and Market Share by Type (2018-2023)
2.3.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sale Price by Type (2018-2023)
2.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Application
2.4.1 Immunotherapy of Cancer
2.4.2 Clinical Experiment
2.5 T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application
2.5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sale Market Share by Application (2018-2023)
2.5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue and Market Share by Application (2018-2023)
2.5.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sale Price by Application (2018-2023)
3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies by Company
3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Breakdown Data by Company
3.1.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Annual Sales by Company (2018-2023)
3.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Company (2018-2023)
3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Annual Revenue by Company (2018-2023)
3.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Company (2018-2023)
3.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Company (2018-2023)
3.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sale Price by Company
3.4 Key Manufacturers T-Cell & NK-Cell Engaging Bispecific Antibodies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers T-Cell & NK-Cell Engaging Bispecific Antibodies Product Location Distribution
3.4.2 Players T-Cell & NK-Cell Engaging Bispecific Antibodies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for T-Cell & NK-Cell Engaging Bispecific Antibodies by Geographic Region
4.1 World Historic T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Geographic Region (2018-2023)
4.1.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Annual Sales by Geographic Region (2018-2023)
4.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country/Region (2018-2023)
4.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Annual Sales by Country/Region (2018-2023)
4.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Annual Revenue by Country/Region (2018-2023)
4.3 Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth
4.4 APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth
4.5 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth
4.6 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth
5 Americas
5.1 Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
5.1.1 Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2018-2023)
5.1.2 Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2018-2023)
5.2 Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type
5.3 Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region
6.1.1 APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2018-2023)
6.1.2 APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2018-2023)
6.2 APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type
6.3 APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies by Country
7.1.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2018-2023)
7.1.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2018-2023)
7.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type
7.3 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies by Country
8.1.1 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2018-2023)
8.1.2 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2018-2023)
8.2 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type
8.3 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of T-Cell & NK-Cell Engaging Bispecific Antibodies
10.3 Manufacturing Process Analysis of T-Cell & NK-Cell Engaging Bispecific Antibodies
10.4 Industry Chain Structure of T-Cell & NK-Cell Engaging Bispecific Antibodies
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors
11.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Customer
12 World Forecast Review for T-Cell & NK-Cell Engaging Bispecific Antibodies by Geographic Region
12.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Forecast by Region
12.1.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecast by Region (2024-2029)
12.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecast by Type
12.7 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecast by Application
13 Key Players Analysis
13.1 AbbVie
13.1.1 AbbVie Company Information
13.1.2 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.1.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AbbVie Main Business Overview
13.1.5 AbbVie Latest Developments
13.2 Astellas Pharma
13.2.1 Astellas Pharma Company Information
13.2.2 Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.2.3 Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Astellas Pharma Main Business Overview
13.2.5 Astellas Pharma Latest Developments
13.3 GEMoaB Monoclonals
13.3.1 GEMoaB Monoclonals Company Information
13.3.2 GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.3.3 GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GEMoaB Monoclonals Main Business Overview
13.3.5 GEMoaB Monoclonals Latest Developments
13.4 Immunocore
13.4.1 Immunocore Company Information
13.4.2 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.4.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Immunocore Main Business Overview
13.4.5 Immunocore Latest Developments
13.5 Molecular Partners
13.5.1 Molecular Partners Company Information
13.5.2 Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.5.3 Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Molecular Partners Main Business Overview
13.5.5 Molecular Partners Latest Developments
13.6 Roche
13.6.1 Roche Company Information
13.6.2 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.6.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Roche Main Business Overview
13.6.5 Roche Latest Developments
13.7 AstraZeneca
13.7.1 AstraZeneca Company Information
13.7.2 AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.7.3 AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 AstraZeneca Main Business Overview
13.7.5 AstraZeneca Latest Developments
13.8 Merck & Co.
13.8.1 Merck & Co. Company Information
13.8.2 Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.8.3 Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Merck & Co. Main Business Overview
13.8.5 Merck & Co. Latest Developments
13.9 Pfizer
13.9.1 Pfizer Company Information
13.9.2 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.9.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Pfizer Main Business Overview
13.9.5 Pfizer Latest Developments
13.10 Eli Lilly
13.10.1 Eli Lilly Company Information
13.10.2 Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.10.3 Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Eli Lilly Main Business Overview
13.10.5 Eli Lilly Latest Developments
13.11 IGM Biosciences
13.11.1 IGM Biosciences Company Information
13.11.2 IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.11.3 IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 IGM Biosciences Main Business Overview
13.11.5 IGM Biosciences Latest Developments
13.12 Novartis
13.12.1 Novartis Company Information
13.12.2 Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.12.3 Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Novartis Main Business Overview
13.12.5 Novartis Latest Developments
13.13 BenHealth Biopharmaceuticals
13.13.1 BenHealth Biopharmaceuticals Company Information
13.13.2 BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.13.3 BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 BenHealth Biopharmaceuticals Main Business Overview
13.13.5 BenHealth Biopharmaceuticals Latest Developments
13.14 CytomX Therapeutics
13.14.1 CytomX Therapeutics Company Information
13.14.2 CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.14.3 CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 CytomX Therapeutics Main Business Overview
13.14.5 CytomX Therapeutics Latest Developments
13.15 Janssen
13.15.1 Janssen Company Information
13.15.2 Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.15.3 Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Janssen Main Business Overview
13.15.5 Janssen Latest Developments
13.16 Lava Therapeutics
13.16.1 Lava Therapeutics Company Information
13.16.2 Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.16.3 Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Lava Therapeutics Main Business Overview
13.16.5 Lava Therapeutics Latest Developments
13.17 MacroGenics
13.17.1 MacroGenics Company Information
13.17.2 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.17.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 MacroGenics Main Business Overview
13.17.5 MacroGenics Latest Developments
13.18 Maverick Therapeutics
13.18.1 Maverick Therapeutics Company Information
13.18.2 Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.18.3 Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Maverick Therapeutics Main Business Overview
13.18.5 Maverick Therapeutics Latest Developments
13.19 VBL Therapeutics
13.19.1 VBL Therapeutics Company Information
13.19.2 VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.19.3 VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 VBL Therapeutics Main Business Overview
13.19.5 VBL Therapeutics Latest Developments
13.20 Amgen
13.20.1 Amgen Company Information
13.20.2 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
13.20.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Amgen Main Business Overview
13.20.5 Amgen Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. T-Cell & NK-Cell Engaging Bispecific Antibodies Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. T-Cell & NK-Cell Engaging Bispecific Antibodies Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Recombinant Monoclonal Antibodies
Table 4. Major Players of In-House Bispecific Antibodies
Table 5. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2018-2023) & (ml)
Table 6. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2018-2023)
Table 7. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2018-2023) & ($ million)
Table 8. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2018-2023)
Table 9. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sale Price by Type (2018-2023) & (US$/ml)
Table 10. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2018-2023) & (ml)
Table 11. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2018-2023)
Table 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2018-2023)
Table 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2018-2023)
Table 14. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sale Price by Application (2018-2023) & (US$/ml)
Table 15. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Company (2018-2023) & (ml)
Table 16. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Company (2018-2023)
Table 17. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Company (2018-2023) ($ Millions)
Table 18. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Company (2018-2023)
Table 19. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sale Price by Company (2018-2023) & (US$/ml)
Table 20. Key Manufacturers T-Cell & NK-Cell Engaging Bispecific Antibodies Producing Area Distribution and Sales Area
Table 21. Players T-Cell & NK-Cell Engaging Bispecific Antibodies Products Offered
Table 22. T-Cell & NK-Cell Engaging Bispecific Antibodies Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Geographic Region (2018-2023) & (ml)
Table 26. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share Geographic Region (2018-2023)
Table 27. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country/Region (2018-2023) & (ml)
Table 30. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country/Region (2018-2023)
Table 31. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2018-2023) & (ml)
Table 34. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2018-2023)
Table 35. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country (2018-2023)
Table 37. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2018-2023) & (ml)
Table 38. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2018-2023) & (ml)
Table 39. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2018-2023) & (ml)
Table 40. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Region (2018-2023)
Table 41. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Region (2018-2023)
Table 43. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2018-2023) & (ml)
Table 44. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2018-2023) & (ml)
Table 45. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2018-2023) & (ml)
Table 46. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2018-2023)
Table 47. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country (2018-2023)
Table 49. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2018-2023) & (ml)
Table 50. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2018-2023) & (ml)
Table 51. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2018-2023) & (ml)
Table 52. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2018-2023) & (ml)
Table 56. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2018-2023) & (ml)
Table 57. Key Market Drivers & Growth Opportunities of T-Cell & NK-Cell Engaging Bispecific Antibodies
Table 58. Key Market Challenges & Risks of T-Cell & NK-Cell Engaging Bispecific Antibodies
Table 59. Key Industry Trends of T-Cell & NK-Cell Engaging Bispecific Antibodies
Table 60. T-Cell & NK-Cell Engaging Bispecific Antibodies Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors List
Table 63. T-Cell & NK-Cell Engaging Bispecific Antibodies Customer List
Table 64. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecast by Region (2024-2029) & (ml)
Table 65. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecast by Country (2024-2029) & (ml)
Table 67. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecast by Region (2024-2029) & (ml)
Table 69. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecast by Country (2024-2029) & (ml)
Table 71. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecast by Country (2024-2029) & (ml)
Table 73. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecast by Type (2024-2029) & (ml)
Table 75. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecast by Application (2024-2029) & (ml)
Table 77. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. AbbVie Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 79. AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 80. AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 81. AbbVie Main Business
Table 82. AbbVie Latest Developments
Table 83. Astellas Pharma Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 84. Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 85. Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 86. Astellas Pharma Main Business
Table 87. Astellas Pharma Latest Developments
Table 88. GEMoaB Monoclonals Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 89. GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 90. GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 91. GEMoaB Monoclonals Main Business
Table 92. GEMoaB Monoclonals Latest Developments
Table 93. Immunocore Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 94. Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 95. Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 96. Immunocore Main Business
Table 97. Immunocore Latest Developments
Table 98. Molecular Partners Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 99. Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 100. Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 101. Molecular Partners Main Business
Table 102. Molecular Partners Latest Developments
Table 103. Roche Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 104. Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 105. Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 106. Roche Main Business
Table 107. Roche Latest Developments
Table 108. AstraZeneca Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 109. AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 110. AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 111. AstraZeneca Main Business
Table 112. AstraZeneca Latest Developments
Table 113. Merck & Co. Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 114. Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 115. Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 116. Merck & Co. Main Business
Table 117. Merck & Co. Latest Developments
Table 118. Pfizer Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 119. Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 120. Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 121. Pfizer Main Business
Table 122. Pfizer Latest Developments
Table 123. Eli Lilly Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 124. Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 125. Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 126. Eli Lilly Main Business
Table 127. Eli Lilly Latest Developments
Table 128. IGM Biosciences Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 129. IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 130. IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 131. IGM Biosciences Main Business
Table 132. IGM Biosciences Latest Developments
Table 133. Novartis Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 134. Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 135. Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 136. Novartis Main Business
Table 137. Novartis Latest Developments
Table 138. BenHealth Biopharmaceuticals Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 139. BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 140. BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 141. BenHealth Biopharmaceuticals Main Business
Table 142. BenHealth Biopharmaceuticals Latest Developments
Table 143. CytomX Therapeutics Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 144. CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 145. CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 146. CytomX Therapeutics Main Business
Table 147. CytomX Therapeutics Latest Developments
Table 148. Janssen Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 149. Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 150. Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 151. Janssen Main Business
Table 152. Janssen Latest Developments
Table 153. Lava Therapeutics Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 154. Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 155. Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 156. Lava Therapeutics Main Business
Table 157. Lava Therapeutics Latest Developments
Table 158. MacroGenics Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 159. MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 160. MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 161. MacroGenics Main Business
Table 162. MacroGenics Latest Developments
Table 163. Maverick Therapeutics Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 164. Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 165. Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 166. Maverick Therapeutics Main Business
Table 167. Maverick Therapeutics Latest Developments
Table 168. VBL Therapeutics Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 169. VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 170. VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 171. VBL Therapeutics Main Business
Table 172. VBL Therapeutics Latest Developments
Table 173. Amgen Basic Information, T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 174. Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolios and Specifications
Table 175. Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue ($ Million), Price (US$/ml) and Gross Margin (2018-2023)
Table 176. Amgen Main Business
Table 177. Amgen Latest Developments
List of Figures
Figure 1. Picture of T-Cell & NK-Cell Engaging Bispecific Antibodies
Figure 2. T-Cell & NK-Cell Engaging Bispecific Antibodies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate 2018-2029 (ml)
Figure 7. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Recombinant Monoclonal Antibodies
Figure 10. Product Picture of In-House Bispecific Antibodies
Figure 11. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type in 2022
Figure 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2018-2023)
Figure 13. T-Cell & NK-Cell Engaging Bispecific Antibodies Consumed in Immunotherapy of Cancer
Figure 14. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market: Immunotherapy of Cancer (2018-2023) & (ml)
Figure 15. T-Cell & NK-Cell Engaging Bispecific Antibodies Consumed in Clinical Experiment
Figure 16. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market: Clinical Experiment (2018-2023) & (ml)
Figure 17. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2022)
Figure 18. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application in 2022
Figure 19. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market by Company in 2022 (ml)
Figure 20. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Company in 2022
Figure 21. T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market by Company in 2022 ($ Million)
Figure 22. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Company in 2022
Figure 23. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Geographic Region (2018-2023)
Figure 24. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Geographic Region in 2022
Figure 25. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales 2018-2023 (ml)
Figure 26. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue 2018-2023 ($ Millions)
Figure 27. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales 2018-2023 (ml)
Figure 28. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue 2018-2023 ($ Millions)
Figure 29. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales 2018-2023 (ml)
Figure 30. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue 2018-2023 ($ Millions)
Figure 31. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales 2018-2023 (ml)
Figure 32. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue 2018-2023 ($ Millions)
Figure 33. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country in 2022
Figure 34. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country in 2022
Figure 35. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2018-2023)
Figure 36. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2018-2023)
Figure 37. United States T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 38. Canada T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 39. Mexico T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 40. Brazil T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 41. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Region in 2022
Figure 42. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Regions in 2022
Figure 43. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2018-2023)
Figure 44. APAC T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2018-2023)
Figure 45. China T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 46. Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 47. South Korea T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 48. Southeast Asia T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 49. India T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 50. Australia T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 51. China Taiwan T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 52. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country in 2022
Figure 53. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country in 2022
Figure 54. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2018-2023)
Figure 55. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2018-2023)
Figure 56. Germany T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 57. France T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 58. UK T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 59. Italy T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 60. Russia T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 61. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country in 2022
Figure 62. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country in 2022
Figure 63. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2018-2023)
Figure 64. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2018-2023)
Figure 65. Egypt T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 66. South Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 67. Israel T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 68. Turkey T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 69. GCC Country T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth 2018-2023 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of T-Cell & NK-Cell Engaging Bispecific Antibodies in 2022
Figure 71. Manufacturing Process Analysis of T-Cell & NK-Cell Engaging Bispecific Antibodies
Figure 72. Industry Chain Structure of T-Cell & NK-Cell Engaging Bispecific Antibodies
Figure 73. Channels of Distribution
Figure 74. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Forecast by Region (2024-2029)
Figure 75. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share Forecast by Region (2024-2029)
Figure 76. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share Forecast by Type (2024-2029)
Figure 77. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share Forecast by Type (2024-2029)
Figure 78. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share Forecast by Application (2024-2029)
Figure 79. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share Forecast by Application (2024-2029)

※参考情報

T細胞・NK細胞結合型二重特異性抗体は、近年のがん免疫療法において注目を集めている治療戦略の一つです。これらの抗体は、特定の腫瘍抗原とT細胞や自然免疫系の細胞（NK細胞）に同時に結合できる特性を持っています。このような特別な抗体は、腫瘍細胞をより効果的に攻撃することを目的としています。

二重特異性抗体の基本的な概念は、2つの異なる抗原に対して同時に結合する能力を持つ抗体を生成することです。これにより、異なる免疫細胞（T細胞やNK細胞）を腫瘍細胞に接近させることが可能になります。これが生物学的に強力な相互作用を引き起こし、腫瘍細胞の認識と排除を促進します。

T細胞は、特定の抗原を持つ細胞を特異的に認識し、攻撃する役割を持ちます。これに対し、NK細胞は主にウイルス感染細胞や腫瘍細胞を非特異的に攻撃します。二重特異性抗体は、これらの免疫細胞を腫瘍に誘導することで、より効率的な免疫応答を引き起こすことが期待されています。

この抗体の特徴の一つは、その多様性にあります。二重特異性抗体には、いくつかの設計アプローチがあり、使用される技術によってさまざまな形態の抗体が開発されています。例えば、ハイブリッド抗体やフュージョンタンパク質、scFv（単鎖可変フラグメント）を用いた抗体などがあります。これらの技術はそれぞれ利点と欠点があり、目的に応じて最適なものが選択されます。

また、二重特異性抗体は、がん細胞の表面に発現する特定の抗原と、T細胞のCD3分子やNK細胞の活性化マーカーに結合することが一般的です。これにより、T細胞やNK細胞はがん細胞へ近づき、活性化されることで、効果的に腫瘍細胞を排除します。

これらの抗体の用途は主にがん治療に集中しています。多くの研究開発が進行中で、さまざまながん種に対して効果が期待されています。例えば、白血病やリンパ腫、固形腫瘍などに対しての臨床試験が行われており、一部の製品はすでに市場に出ています。

また、T細胞・NK細胞結合型二重特異性抗体の関連技術も重要です。例えば、抗体医薬品の製造技術や評価法（中和抗体の確認や生体内動態の評価など）などが含まれます。これらの技術は、抗体の開発とその効力を高め、患者にとっての利便性を向上させるために不可欠です。

このように、T細胞・NK細胞結合型二重特異性抗体は、がん治療における新たな武器として、既存の治療法と組み合わせることで、より良い治療効果を引き出すことができると期待されています。今後の研究と開発によって、さらに多くの患者に恩恵をもたらすことが期待されているのです。将来的には、これらの抗体を用いた治療法が、がん治療の新たなスタンダードとなる可能性があるでしょう。


★調査レポート[世界のT細胞・NK細胞結合型二重特異性抗体市場予測 2023年-2029年] (コード：LP23MY3711)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のT細胞・NK細胞結合型二重特異性抗体市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のT細胞・NK細胞結合型バイスペシフィック抗体市場：主要プレイヤーの市場シェアとランキング2024年

    • ◆H&Iグローバルリサーチのお客様（例）◆